eli lilly and company retatrutide Retatrutide, Lilly's next obesity drug, fueled dramatic weight loss in clinical trial Lilly's Retatrutide Continues To Show

Adapt them slightly to account for increased appetite by increasing portion sizes of protein and vegetables while keeping calorie-dense foods measured

The TRIUMPH-1 results suggest Retatrutide may support more significant weight loss

A protocol built around fewer, less frequent draws will naturally extend a vials usable life relative to one built around frequent, high-volume sampling which is why supply duration varies across research settings even when starting from an identical 10mg vial

Retatrutide adds the glucagon component, which can contribute to increased heart rate and potential blood glucose fluctuations in some individuals